Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of L'Aquila
Age
40–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
male or female patients, aged between 40 and 70 years, referring to the Headache Center of the University of L'Aquila;
a diagnosis of migraine with or without aura according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3; https://ichd-3.org/);
age at onset of migraine \<50 years;
migraine must have been present for at least ≥ 12 months;
treated with CGRP-MAbs (erenumab, fremanezumab or galcanezumab) according to clinical practice criteria for 90-180 days since the first subcutaneous administration (this time range was chosen to ensure a stable CGRP pathway inhibition);
reporting \>4 monthly migraine days in the last 30 days of observation despite treatment with CGRP-MAbs;
able to discriminate between migraine and tension-type headaches;
written informed consent to participate in the study
You may not be if
any migraine preventive medication other than CGRP-MAbs;
secondary migraine;
epilepsy or any other neurologic condition that may be worsened by transcranial electrical stimulation;
metallic head implants, cardiac pacemaker or any other device that could malfunction or be displaced by electrical stimulation;
